& Events
& Events
News
& Events
Oct 19, 2022 Inversago Pharma Announces Appointment of Ed Mathers, BSc and Nanna Lüneborg, PhD, MBA to its Board of Directors
– Board appointments following recent $95 million CAD Series C Financing MONTREAL (CANADA) – October 19, 2022 – Inversago Pharma Inc. (“Inversago”), a clinical stage biotech company with a unique portfolio of peripherally-acting CB1 inverse agonists, today announced the appointment of two new board members: Ed Mathers, BSc, General Partner at New Enterprise Associates (“NEA”) […]
Oct 17, 2022 Inversago Pharma Raises $95 million CAD in Series C Financing
– Series C financing led by NEA – Provides advancement of INV-202 Phase 2 clinical trial in Diabetic Kidney Disease in Q4 MONTREAL (CANADA) – October 17, 2022 – Inversago Pharma Inc. (“Inversago”), a clinical stage biotech company with a unique portfolio of peripherally-acting CB1 inverse agonists, today announced the completion of a Series C […]
Sep 29, 2022 Inversago Pharma Awarded the ʻPromising Health Biotech Company of the Yearʼ Gold Leaf Award at the BIONATION Conference in Ottawa
MONTREAL (CANADA) – September 29, 2022 – Inversago Pharma Inc. (“Inversago”), a clinical stage biotech company with a unique portfolio of peripherally-acting CB1 inverse agonists, today announces the Company was awarded the ʻPromising Health Biotech Company of the Yearʼ Gold Leaf Award at the BIONATION Conference, currently held in Ottawa, Canada. An initiative of BIOTECanada, […]
Sep 15, 2022 Inversago Pharma receives IND clearance for Phase 2 trial of INV-202 in Diabetic Kidney Disease
– FDA clears IND of First-In-Class, Peripherally-Acting CB1 Inverse Agonist INV-202 – Phase 2 trial in Diabetic Kidney Disease will also provide data in complications of diabetes, metabolic syndrome and dyslipidemia MONTREAL (CANADA) – September 15, 2022 – Inversago Pharma Inc. (“Inversago”), a clinical stage biotech company with a unique portfolio of peripherally-acting CB1 inverse […]